Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models
- 30 October 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 74 (2) , 432-441
Abstract
Several population pharmacokinetic (PopPK) models for meropenem dosing in ICU patients are available. It is not known to what extent these models can predict meropenem concentrations in an independent validation dataset when meropenem is infused continuously. A PopPK model was developed with concentration-time data collected from routine care of 21 ICU patients (38 samples) receiving continuous infusion meropenem. The predictability of this model and seven other published PopPK models was studied using an independent dataset that consisted of 47 ICU patients (161 samples) receiving continuous infusion meropenem. A statistical comparison of imprecision (mean square prediction error) and bias (mean prediction error) was conducted. A one-compartment model with linear elimination and creatinine clearance as a covariate of clearance best described our data. The mean ± SD parameter estimate for CL was 9.89 ± 3.71 L/h. The estimated volume of distribution was 48.1 L. The different PopPK models showed a bias in predicting serum concentrations from the validation dataset that ranged from -8.76 to 7.06 mg/L. Imprecision ranged from 9.90 to 42.1 mg/L. Published PopPK models for meropenem vary considerably in their predictive performance when validated in an external dataset of ICU patients receiving continuous infusion meropenem. It is necessary to validate PopPK models in a target population before implementing them in a therapeutic drug monitoring program aimed at optimizing meropenem dosing.Keywords
Funding Information
- Centre of Research Excellence (APP1099452)
- Australian National Health and Medical Research Council (APP1117065)
- Research Foundation Flanders (1881015N)
This publication has 34 references indexed in Scilit:
- Antibacterial drug development program successes and failures: a pharmacometric explanationCurrent Opinion in Pharmacology, 2017
- Right Dose, Right Now: Customized Drug Dosing in the Critically IllCritical Care Medicine, 2017
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016Intensive Care Medicine, 2017
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic SocietyClinical Infectious Diseases, 2016
- Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial TherapyAntimicrobial Agents and Chemotherapy, 2014
- Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutionsThe Lancet Infectious Diseases, 2014
- Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactamsCritical Care, 2011
- Pharmacokinetics and Pharmacodynamics of AntimicrobialsClinical Infectious Diseases, 2007
- Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated PneumoniaChest, 2002
- Inadequate Antimicrobial Treatment of InfectionsChest, 1999